☆ 4.6 Letter

Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study

BLOOD ADVANCES (2022)

Get Full Text
Add to Collection

Journal

BLOOD ADVANCES
Volume 6, Issue 16, Pages 4736-4739

Publisher

ELSEVIER
DOI: 10.1182/bloodadvances.2022007782

Keywords

-

Categories

Hematology

Funding

  1. ADC Therapeutics, SA
  2. Peykoff Initiative of the Lymphoma Research Foundation

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.